Linked Life Data

11762177

Source:http://linkedlifedata.com/resource/pubmed/id/11762177

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2001-12-12
pubmed:abstractText
The efficacy and safety of docetaxel were evaluated in an open, multicentric, non comparative study involving 24 patients with locally advanced or metastatic breast cancer, eligible for second line or subsequent anticancer chemotherapy; the results confirm a global response around 50%, suggesting some advantages when compared to the usual treatments in this set of patients; the median duration of response, the median time to progression and the median time of survival were respectively, 309, 219 and 345 days; the main iatrogenic event was haematological, mainly in the white and red blood cells.
pubmed:language
por
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0870-399X
pubmed:author
pubmed:issnType
Print
pubmed:volume
14
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
375-80
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:articleTitle
[Multicenter open study with docetaxel. Treatment of patients with locally advanced or metastatic breast carcinoma].
pubmed:affiliation
Maternidade Bissaya Barreto, Coimbra.
pubmed:publicationType
Journal Article, Clinical Trial, English Abstract, Multicenter Study